Menu

Eli Lilly

New 2016 ACC/AHA Guideline Focused Update States that it is Reasonable to Choose Effient® (prasugrel) Over Clopidogrel for Certain ACS-PCI Patients with ST-Elevation Myocardial Infarction and NSTE-ACS

, , , ,

Class IIa recommendation provided for maintenance use of Effient in ACS-PCI STEMI and NSTE-ACS patients who are not at high risk for bleeding complications and who do not have a history of stroke or transient ischemic attack PARSIPPANY, N.J. and INDIANAPOLIS, March 31, 2016 /PRNewswire/ — A new guideline focused update provided oral antiplatelet therapy […]

Lilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation

, , , ,

Company supports Diabetes Scholars Foundation Scholarship fund for fourth year in a row ROLLING MEADOWS, Ill. and INDIANAPOLIS, Feb. 11, 2016 /PRNewswire/ — Attending college is a major milestone for many young people, but for those with type 1 diabetes, the journey can be extra demanding. Not only do these students juggle class schedules, assignments […]

American Diabetes Association® Survey Shows Summer Camp Can Positively Impact Children’s Disease Management Skills, Confidence and Stress

, , , ,

Lilly Diabetes commits $93,000 to support Association “Camperships” INDIANAPOLIS and ALEXANDRIA, Va., Feb. 3, 2016 /PRNewswire/ — A three-year survey by the American Diabetes Association (Association) shows attending summer camp can do much more than lift the spirits of children with type 1 diabetes. Surveys conducted with caregivers before and after their child attended an […]

Lilly and Roche Diagnostics to Collaborate on Alzheimer’s Disease Adjunct Diagnostic Tool

, , , ,

INDIANAPOLIS, Jan. 27, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42. Together with tau tangles, the presence of amyloid in the brain is a key marker of Alzheimer’s disease, a condition […]

FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment

, , , ,

– BASAGLAR is the first FDA-approved follow-on insulin glargine treatment – BASAGLAR will be available in the U.S. starting on December 15, 2016 INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 16, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) granted […]

CHMP Recommends Lilly and Boehringer Ingelheim’s Investigational New Insulin Glargine Product for Approval in the European Union

, , , , ,

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ — The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 […]

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA

, , , , ,

— No additional clinical trials requested by the FDA RIDGEFIELD, Conn. and INDIANAPOLIS, June 17, 2014 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with […]

Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product

, , , , ,

New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 20, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an […]

Lilly Diabetes/Disney Custom Books for Type 1 Diabetes Families Now Available Online

, , , ,

New resources housed on T1EverydayMagic.com combine the expertise of Lilly Diabetes with the magic of Disney INDIANAPOLIS, Dec. 19, 2013 /PRNewswire/ — Lilly Diabetes and Disney today announced that their custom books for children and families with type 1 diabetes are now available online. The digital books explore real-life challenges and stories of children with […]

1 2